Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

June 2nd 2018

ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

June 2nd 2018

Practice Changes for Use of Immunotherapy in NSCLC

June 2nd 2018

OncLive News Network On Location: In Chicago Monday, June 4

June 2nd 2018

OncLive News Network On Location: In Chicago Sunday, June 3

June 2nd 2018

OncLive News Network On Location: In Chicago Saturday, June 2

June 2nd 2018

OncLive News Network On Location: In Chicago Friday, June 1

June 2nd 2018

Pomalidomide Triplet Extends PFS in Relapsed/Refractory Myeloma

June 2nd 2018

Adding pomalidomide (Pomalyst) to bortezomib (Velcade) and low-dose dexamethasone reduced the risk of disease progression or death by 39% in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide.

Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma

June 2nd 2018

The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.

Studies Stopped for Daratumumab/Checkpoint Inhibitor Combos in NSCLC, Myeloma

May 29th 2018

Two separate early-phase clinical trials exploring daratumumab in combination with either a PD-1 inhibitor for multiple myeloma or a PD-L1 inhibitor for non–small cell lung cancer were terminated following a planned interim analysis.

Dr. Htut on Immunotherapy in Multiple Myeloma

May 25th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

Selinexor Tested in Combination With Standard Therapy in Multiple Myeloma

May 25th 2018

The BOSTON trial is randomizing patients with relapsed/refractory multiple myeloma to a triplet combination of selinexor (KPT-330), bortezomib (Velcade), and dexamethasone versus a combination of bortezomib and dexamethasone.

New Upfront Strategies Emerge for Multiple Myeloma

May 18th 2018

A. Keith Stewart, MB, ChB, and a panel of hematology experts review data concerning emerging frontline strategies for multiple myeloma that were presented at the 2017 ASH Annual Meeting.

ASCO Panel Sees Greater Utility for Bone-Modifying Agents in Myeloma

May 17th 2018

In updated guidelines exploring the role of bone-modifying agents, ASCO has recommended expanding the use of bisphosphonates to include all patients being treated for active multiple myeloma.

Wolf Emphasizes the Importance of Phrasing in Multiple Myeloma

May 17th 2018

Jeffrey Wolf, MD, emphasizes the importance of identifying risk when diagnosing patients with multiple myeloma.

Expert Summarizes Strides in Relapsed Myeloma, Says More to Come

May 8th 2018

Peter Voorhees, MD, discusses treatments for patients with early relapsed multiple myeloma and previews future research efforts.

Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

May 8th 2018

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

FDA Approves Frontline Daratumumab/VMP Combo for Multiple Myeloma

May 8th 2018

The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Bergsagel on Treatment Options for Relapsed/Refractory Myeloma

May 7th 2018

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses treatment options for patients with relapsed/refractory multiple myeloma.

Usmani Discusses MRD and Other Myeloma Developments

May 2nd 2018

Saad Z. Usmani, MD, discusses the clinical applications of minimal residual disease and managing patients with relapsed/refractory multiple myeloma.